Compare SGN & KALA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SGN | KALA |
|---|---|---|
| Founded | 2019 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.7M | 5.1M |
| IPO Year | 2023 | 2017 |
| Metric | SGN | KALA |
|---|---|---|
| Price | $1.13 | $0.60 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $31.50 |
| AVG Volume (30 Days) | 254.8K | ★ 21.5M |
| Earning Date | 11-12-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $366,344.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.44 | $0.61 |
| 52 Week High | $7.24 | $20.60 |
| Indicator | SGN | KALA |
|---|---|---|
| Relative Strength Index (RSI) | 41.01 | 34.58 |
| Support Level | $1.17 | $0.67 |
| Resistance Level | $1.32 | $0.86 |
| Average True Range (ATR) | 0.13 | 0.24 |
| MACD | 0.01 | 0.07 |
| Stochastic Oscillator | 41.46 | 0.16 |
Signing Day Sports Inc is a technology company developing and operating platforms aiming to allow significantly more student-athletes to go to college and continue playing sports. Its platform Signing Day Sports is a digital ecosystem to help athletes get discovered and recruited by coaches and recruiters across the country. It currently fully supports football and baseball, and it plans to expand the Signing Day Sports platform to include additional sports.
Kala Bio Inc is a biopharmaceutical company. The company is a clinical-stage biopharmaceutical company dedicated to researching, developing, and commercializing therapies for rare and severe eye diseases. KALA'smain product candidate, KPI-012, is a human MSC-S, which contains numerous human-derived biofactors, such as growth factors, protease inhibitors, matrix proteins, and neurotrophic factors that can potentially correct the impaired corneal healing that is an underlying etiology of multiple severe ocular diseases. Its MSC-S platform is for retinal degenerative diseases, such as Retinitis Pigmentosa and Stargardt Disease.